Effects of fulvestrant, an estrogen receptor antagonist on MMQ cells and its mechanism

Neuroendocrinology Letters

Volumn 30, Issue 2, 2009, Pages 268-274

  Li, Chuzhong ^a   Sun, Zelin ^a   Gui, Songbai ^b   Liu, Fangjun ^c   Zhang, Yazhuo ^d  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Estrogen receptor; Fulvestrant; MAPK pathway; MMQ; Prolactin

Indexed keywords

ESTROGEN RECEPTOR; FULVESTRANT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROLACTIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; IN VITRO STUDY; NONHUMAN; PROLACTIN RELEASE; PROLACTINOMA; RAT; RECEPTOR DOWN REGULATION;

EID: 70349334218     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Aronica SM, Kraus WL, Katzenellenbogen BS (1994). Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci USA. 91: 8517-8521.
2. Bulayeva NN, Watson CS (2004). Xenoestrogen-induced ERK-1 and ERK-2 activation via multiple membrane-initiated signaling pathways. Environ Health Perspect. 112: 1481-11387
3. Bunone G, Briand PA, Miksicek RJ, et al (1996). Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15: 2174-2183. (Pubitemid 26141134)
4. Chaidarun SS, Eggo MC, Stewart PM, et al (1994). Role of growth factors and estrogen as modulators and growth, differentiation and expression of gonadotropin subunit genes in primary cultured sheep pituitary cells. Endocrinology. 134: 935-944.
5. Chun Y, Gregg D, Sarkar D, et al (1998). Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth. Proc Natl Acad Sci USA. 95: 2325-2330. (Pubitemid 28145940)
6. Collins P, Webb C (1999). Estrogen hits the surface. Nature Med. 5: 1130-1131.
7. Dauvois S, White R, Parker MG (1993). The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 106: 1377-1388. (Pubitemid 24018422)
8. Dubai DB, Shughrue PJ, Wilson ME, et al (1999). Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors. J Neurosci. 19: 6385-6393.
9. El Etreby MF, Liang Y, Wrenn RW, et al (1998). Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 51: 149-168. (Pubitemid 28561420)
10. English J, Pearson G, Wilsbacher J, et al (1999). New insights into the control of MAP kinase pathways. Exp Cell Res. 253: 255-270.
11. Fawell SE, White R, Hoare S, et al (1990). Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Nat Acad Sci USA. 87: 6883-6887.
12. Filardo EJ, Quinn JA, Bland KI, et al (2000). Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through secretion of HB-EGF. Mol Endocrinol. 14: 1649-1660.
13. Filardo EJ, Quinn JA, Frackelton AR Jr, et al (2002). Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis. Mol Endocrinol. 16: 70-84.
14. Frasor J, Stossi F, Danes JM, et al (2004). Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 64: 1522-1533. (Pubitemid 38235626)
15. Gooren LJ, Assies J, Asscheman H, et al (1988). Estrogen-induced prolactinoma in a man. J Clin Endocrinol Metab. 66: 444-446.
16. Holmgren U, Bergstrand G, Hagenfeldt K, et al (1986). Women with prolactinoma-effect of pregnancy and lactation on serum prolactin and on tumor growth. Acta Endocrinol (Copenh). 111: 452-459. (Pubitemid 16086309)
17. Hoshino R, Chatani Y, Yamori T et al (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 18: 813-822. (Pubitemid 29080340)
18. Improta-Brears T, Whorton AR, Codazzi F, et al (1999). Estrogen-induced activation of mitogen-activated protein kinase requires mobilization of intracellular calcium. Proc Nat Acad Sci USA. 96: 4686-4691. (Pubitemid 29190397)
19. Ignar-Trowbridge DM, Teng CT, Ross KA, et al (1993). Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol. 7: 992-998. (Pubitemid 23252338)
20. Ignar-Trowbridge DM, Pimentel M, Parker MG, et al (1996). Peptide growth factor cross-talk with estrogen receptor requires the A/B domain and occurs independently of protein kinase C or estradiol. Endocrinol. 137: 1735-1744. (Pubitemid 26133949)
21. Kato S, Endoh H, Masuhiro Y, et al (1995). Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270: 1491-1494.
22. Kelly MJ, Lagrange AH, Wagner EJ, et al (1999). Rapid effects of estrogen to modulate G protein-coupled receptors via activation of protein kinase A and protein kinase C pathways. Steroids. 64: 64-75.
23. Kyprianou N, English HF, Davidson NE, et al (1991). Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. 51: 162-166. (Pubitemid 20194126)
24. Lieberman ME, Maurer RA, Claude P, et al (1980). Regulation of pituitary growth and prolactin gene expression by estrogen, hormones and cancer. In: Leavitt WW, ed. Hormones and cancer. Plenum Press: New York. p. 151-163.
25. Lloyd RV (1983). Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland. Am J Pathol. 113: 198-206.
26. Nadal A, Rovira JM, Laribi O, et al (1998). Rapid insulinotropic effect of 17-β-estradiol via a plasma membrane receptor. FASEB J. 12: 1341-1348. (Pubitemid 28475575)
27. Newton CJ, Buric R, Trapp T, et al (1994). The unliganded estrogen receptor (ER) transduces growth factor signals. J Steroid Biochem Mol Biol. 48: 481-486. (Pubitemid 24171874)
28. Perillo B, Sasso A, Abbondanza C, et al (2000). 17-beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol Cell Biol. 20: 2890-2901. (Pubitemid 30183508)
29. Pollard JW, Pacey J, Cheng SV, et al (1987). Estrogens and cell death in murine uterine luminal epithelium. Cell Tissue Res. 249: 533-540. (Pubitemid 18032105)
30. Razandi M, Pedram A, Park ST, et al (2003). Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem. 278: 2701-2712. (Pubitemid 36801351)
31. Sawada H, Ibi M, Kihara T, et al (2000). Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J. 14: 1202-1214. (Pubitemid 30350402)
32. Serri O, Noiseux D, Robert F, et al (1996). Lactotroph hyperplasia in an estrogen treated male-to-female transsexual patient. J Clin Endocrinol Metab. 81: 3177-3179. (Pubitemid 26296184)
33. Shupnik MA, Gharib SD, Chin WW (1989). Divergent effects of estradiol on gonadotropin gene transcription in pituitary fragments. Mol Endocrinol. 3: 474-480.
34. Singer CA, Rogers KL, Strickland TM, et al (1996). Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett. 212: 13-16. (Pubitemid 26267070)
35. Smith CL, Conneely OM, O'Malley BW (1993). Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proc Nat Acad Sci USA. 90: 6120-6124. (Pubitemid 23191466)
36. Wakeling AE, Bowler J (1987). Steroidal pure antioestrogens. J Endocrinol. 112: R7-R10.
37. Watters JJ, Chun T-Y, Kim Y-N, et al (2000). Estrogen modulation of prolactin gene expression requires an intact mitogen-activated protein kinase signal transduction pathway in cultured rat pituitary cells. Mol Endocrinol. 14: 1872-1881.
38. Weigel NL, Zhang Y (1998). Ligand-independent activation of steroid hormone receptors. J Mol Med. 76: 469-479. (Pubitemid 28261256)
39. Wijayaratne AL, Nagel SC, Paige LA, et al (1999). Comparative analyses of mechanistic differences among antioestrogens. Endocrinol. 140: 5828-5840.